Osteoprotegerin lowers type 2 diabetes risk: insights from drug-target Mendelian randomization and mediation analysis
Observational evidence suggests that denosumab, which acts through a mechanism partially analogous to that of the endogenous protein osteoprotegerin (OPG), may be associated with a lower risk of type 2 diabetes (T2D). This raises the possibility that modulation of the OPG pathway may influence diabetes risk. We a...